共查询到20条相似文献,搜索用时 140 毫秒
1.
目的以壳聚糖-海藻酸钠为基质材料,掺杂入纳米ZnS包裹非甾体抗炎药物布洛芬,制备缓、控释性能优异的载药纳米微球;为研发四代新剂型打下基础。方法利用复凝聚法,通过调整添加基质材料速度、反应温度、搅拌速度等,制备含ZnS的壳聚糖海藻酸钠布洛芬纳米微球,透射电镜观察纳米微球的形态,测试纳米微球的载药量与包封率,拟肠液条件下测试所致纳米微球的释放特性。结果含ZnS壳聚糖海藻酸钠布洛芬纳米载药微球的粒径约为80~100nm,载药量为40.2%药物包封率78.2%,ZnS粒径3nm。在水溶液、0.9%NaCl和磷酸盐缓冲液中的吸水膨胀程度小于不含ZnS的载药纳米微球;体外拟肠条件溶出表明含ZnS的载药纳米微球具有良好的缓控释性能,药代动力学特征为被动扩散。结论掺入了ZnS的壳聚糖海藻酸钠布洛芬纳米微球,形状圆整,包封率理想,具有良好的缓控释性能。 相似文献
2.
3.
4.
5.
6.
双嘧达莫缓释微囊的制备与体外评价 总被引:1,自引:0,他引:1
目的:研究以明胶和阿拉伯胶为囊材,将双嘧达莫微囊化的制备工艺。方法:以微囊的药物包封率为制备工艺优化指标,利用复凝聚法,通过正交实验得出微囊的最佳制备工艺条件。结果:囊材与囊心物的质量比2∶1,搅拌转速140r·min-1,固化时间3h、成囊pH4.0、成囊温度为50℃为最佳工艺条件。结论:以最佳制备工艺条件制备含药微囊,重复性好,工艺稳定,同时体外溶出实验表明,该微囊具有较好的缓释作用。 相似文献
7.
喻樊 《中国医院药学杂志》2011,(15)
目的:优选以明胶和阿拉伯胶为囊材制备槲皮素微囊的最佳工艺条件。方法:采用复凝聚法,以槲皮素为囊芯物,用明胶和阿拉伯胶作囊材,取pH、囊材浓度及搅拌速度3个为考察因素,用正交试验探讨制备槲皮素微囊的最佳条件。结果:当pH为4.0,囊材为3%,搅拌速度为150 r.min-1时为最佳工艺条件。结论:本法工艺简便、稳定,具有应用前景。 相似文献
8.
9.
10.
目的采用复凝聚法制备桃金娘油肠溶微囊,并对其体外性质进行评价。方法选用海藻酸钠、氯化钙、壳聚糖为囊材采用复凝聚法制备桃金娘油微囊,用扫描电子显微镜(scanning electron microscope,SEM),Beckman Coulter LS 230激光粒度仪表征了微囊表面形态及粒径,采用顶空进样-GC色谱法测定了载药量和包封率。结果正交设计优化处方和工艺如下:海藻酸钠质量浓度为25g.L-1、壳聚糖质量浓度为3 g.L-1、凝聚速度为5 mL.min-1和凝聚时间为60 min,所得微囊粒径为(14.23±1.45)μm,载药质量分数为(11.3±0.4)%,包封率为(73.6±2.5)%。微囊具有耐酸和肠溶性能,表面褶皱,粒径分布均匀。结论复凝聚法可用于桃金娘油肠溶微囊的制备。 相似文献
11.
尼莫地平壳聚糖缓释微球制备工艺及性能研究 总被引:3,自引:0,他引:3
目的研究以壳聚糖和阿拉伯胶为基质,制备尼莫地平缓释微球的工艺。方法以微球的药物包封率为制备工艺优化指标,得出成球的最佳制备工艺条件。结果最佳工艺条件为:搅拌速度400 r/min,pH 4.5,壳聚糖与阿拉伯胶重量浓度比为1∶1,戊二醛用量为1%。结论以最佳制备工艺条件制备载药微球,重现性好,工艺稳定,同时体外释放实验表明,该微球具有较好的缓释作用。 相似文献
12.
目的:采用复凝聚法制备对乙酰氨基酚(AAP)微囊并考察其体外释药行为。制备AAP复合微囊栓剂,具有良好释放效果。方法:考察复凝聚法制备AAP微囊过程的处方和工艺因素,并进行正交试验设计,筛选出最佳条件制备AAP微囊并考察其体外释药行为。同时采用复合缓释技术(速释部分+微囊缓释)制备复合微囊缓释栓剂,考察其释药行为。结果:建立了复凝聚法制备AAP微囊方法,优化后的制备条件为:明胶阿拉伯胶囊材用量各为7 g(溶液浓度7%),药物用量为8 g,搅拌速度为300 r·min-1,制备温度55℃。此条件制备的微囊形态圆整,粒径均匀,重复性好,包封率为(79.71±0.10)%,载药量为23.11±0.69%。微囊有缓释效果,拟合缓释方程符合一级方程。制备的复合微囊栓与普通栓剂相比,具有更好的释放效果,其中缓释过程药物释放符合Higuchi方程。结论:基于普通栓剂与复合微囊技术制备的新型AAP栓具有更佳的释药特性。 相似文献
13.
萘普生微囊的制备及其质量考察 总被引:1,自引:0,他引:1
目的:制备萘普生微囊并考察其制剂质量。方法:以明胶和阿拉伯胶为囊材,采用复凝聚法将萘普生制成微囊;以阿拉伯胶浓度(A)、萘普生与阿拉伯胶的质量比例(B)和成囊温度(C)为考察因素,包封率为指标设计正交试验优化成囊的最佳制备工艺,并对优化工艺所制得微囊的粒径、包封率、载药量、体外释放性进行考察。结果:最佳工艺条件为A2%、B1:1、C50℃;所制微囊的平均囊径48.92μm,包封率(77.03±1.43)%,载药量(35.31±1.02)%,微囊在48h时体外累积溶出百分率达到91.32%。结论:所制萘普生微囊工艺重现性好、稳定,并具有良好的缓释作用。 相似文献
14.
15.
目的优化岩白菜素微囊的制备工艺,并对制备的岩白菜素微囊进行质量评价。方法以明胶为囊材,单凝聚法制备岩白菜素微囊,通过正交实验设计优化其制备工艺,并对包封率、载药量、平均粒径、体外溶出率进行研究。结果明胶制备岩白菜素微囊的最佳工艺条件为:明胶质量分数为6%,囊心囊材质量比为1∶2,搅拌速度为750r·min^-1。此最佳工艺制备的岩白菜素微囊包封率为75.90%,载药量为23.09%,体外溶出度测定30min为28.6%,12h累计释放达到90%以上。结论以最佳工艺条件制备岩白菜素微囊工艺稳定,包封率高,同时体外释放实验表明,该微囊具有较好的缓释作用。 相似文献
16.
A sustained release suspension of diltiazem, a short half-life calcium channel blocker, was developed to reduce frequency of drug administration, ease of dose adjustment and improve patient compliance. In this study, the sustained release of diltiazem was obtained by complexing the drug with Dowex 50W x 4 and Dowex 50W x 8, strong cationic exchange resins with 4% and 8% degree of cross-linking, respectively. The diltiazem-Dowex 50W x 4 complexes provided the highest drug release and were subsequently used to prepare the microcapsules by emulsion-solvent evaporation method, using 0.75-5.00% cellulose acetate butyrate (CAB) in methylene chloride as a coating solution. As the concentration of CAB increased, the size of microcapsule increased and the drug release from the microcapsule was retarded. From release profile comparison using f(1) and f(2) factors, it was found that the microcapsules coated with 1.75% CAB provided a release profile equivalent to the commercial product of diltiazem sustained release capsule, Herbesser 90SR. Furthermore, sustained release suspensions of the diltiazem microcapsules were formulated with the use of 0.8% sodium carboxymethylcellulose or 0.4% xanthan gum as a suspending agent. The suspension of 0.4% xanthan gum showed superior in physical appearance after 120-day storage at 30 and 45 degrees C. In addition, all sustained release suspensions possessed good stability with low drug leaching and their release profiles were unchanged when compared with the dried microcapsules for 120 days at 30 and 45 degrees C. 相似文献
17.
One of the principal uses suggested for the microencapsulation of pharmaceuticals has been the preparation of the sustained release dosage form. The finished microcapsules have usually been presented in the form of suspensions or gels, but in order to obtain greater sustained release effect a non-disintegrating tablet would be a better formulation. Dihydralazine sulphate (Nepresol) is a dihydralazine-1,4-phthalazine derivative and used as an antihypertensive drug. This work was planned to prepare sustained action preparations of dihydralazine sulphate by microencapsulation and by tabletted microcapsules. Microcapsules were prepared from the microcapsule fractions using biconvex punches with 0.81 cm diameter fitted into a single punch by hand compressor. Avicel PH 101 and lactose were used as disintegrating materials in tablets having 2 kg hardness. Dissolution from both suspended microcapsules and the tablets was studied using the USP XX basket method. A study of in vitro release for both the free and tabletted microcapsules showed basically the same pattern but the time for the release was extended in the case of the tabletted preparations. Dissolution of dihydralazine sulphate was found to be governed by the core: wall ratio, microcapsule size, and the amount and kind of disintegrating agents. Dissolution kinetics were studied and evaluated. 相似文献
18.
19.
《Journal of microencapsulation》2013,30(6):747-751
AbstractMicrocapsules are used for the formulation of drug controlled release and drug targeting dosage forms. Encapsulated hydrophobic drugs are often applied as their solutions in plant oils. The uptake of the oils in the complex coacervate microcapsules can be improved by the addition of surfactants. In this study, soybean, olive and peanut oils were chosen as the representatives of plant oils. The well characterized complex coacervation of gelatin and acacia has been used to produce the microcapsules. The amount of encapsulated oil has been determined gravimetrically. The encapsulation of the oils was high (75–80%). When the surfactants with HLB values from 1.8 to 6.7 were used, the amount of encapsulated oil was high (65–85%). A significant decrease of the oil content in the microcapsules was found when Tween 61 with HLB = 9.6 had been added into the mixture. No oil was found inside the microcapsules from the coacervate emulsion mixture containing Tween 81 (HLB = 10) and Tween 80 (HLB = 15), respectively. The results of the experiment confirm the dependence of hydrophobic substance encapsulation on the HLB published recently for Squalan 相似文献
20.
目的:制备红景天苷微胶囊,测定其包封率,并考察其体外释药特性。方法:以生物相容性良好的壳聚糖和海藻酸钠为囊壁材料,红景天苷药物微粒为囊芯,采用静电吸引层层纳米自组装技术(LBL法)制备红景天苷微胶囊。结果:制备的微胶囊包封率较高,达到78.02±0.72%;不同包裹层数的微胶囊在体外释放速度不同。结论:用LBL法制备的红景天苷微胶囊具有较高的包封率和缓释特性,具有一定的应用前景。 相似文献